Search company, investor...

Predict your next investment

Government
cirm.ca.gov

Investments

22

Portfolio Exits

8

Partners & Customers

6

About California Institute of Regenerative Medicine

California Institute of Regenerative Medicine (CIRM) was created by the people of California to accelerate stem cell treatments to patients with unmet medical needs, and act with a sense of urgency to succeed in that mission. To meet this challenge, CIRM actively partners with both academia and industry in a hands-on, entrepreneurial environment to fast track the development of today's most promising stem cell technologies.

Headquarters Location

210 King Street

San Francisco, California, 94107,

United States

415-396-9100

Want to inform investors similar to California Institute of Regenerative Medicine about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest California Institute of Regenerative Medicine News

Ossium Health Awarded $3.46M in Funding from the California Institute of Regenerative Medicine (CIRM) to Advance the Development of OSSM-007 for the Treatment of Steroid-Refractory Acute Graft versus Host Disease (GVHD)

Apr 28, 2023

SAN FRANCISCO--(BUSINESS WIRE)--Ossium Health, Inc. announced today that the California Institute of Regenerative Medicine (CIRM) has awarded the company a $3.46M Clinical Stage Research Program (CLIN1) grant to support the continued clinical development of OSSM-007, Ossium’s interferon-gamma primed mesenchymal stem cell product, for the treatment of steroid-refractory acute graft versus host disease (GVHD). This funding will support and accelerate pre-clinical and manufacturing activities for

California Institute of Regenerative Medicine Investments

22 Investments

California Institute of Regenerative Medicine has made 22 investments. Their latest investment was in Ossium Health as part of their Grant - III on April 4, 2023.

CBI Logo

California Institute of Regenerative Medicine Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/28/2023

Grant - III

Ossium Health

$3.46M

Yes

2

2/14/2023

Grant

RYNE Bio

$4M

Yes

4

12/19/2022

Grant

Angiocrine Bioscience

$15M

Yes

1

12/15/2022

Grant

Subscribe to see more

$99M

Subscribe to see more

10

10/24/2022

Grant

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/28/2023

2/14/2023

12/19/2022

12/15/2022

10/24/2022

Round

Grant - III

Grant

Grant

Grant

Grant

Company

Ossium Health

RYNE Bio

Angiocrine Bioscience

Subscribe to see more

Subscribe to see more

Amount

$3.46M

$4M

$15M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

4

1

10

10

California Institute of Regenerative Medicine Portfolio Exits

8 Portfolio Exits

California Institute of Regenerative Medicine has 8 portfolio exits. Their latest portfolio exit was ViaCyte on July 11, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/11/2022

Acquired

$99M

9

2/17/2021

Reverse Merger

Subscribe to see more

$99M

Subscribe to see more

10

9/3/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

10/31/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/28/2018

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/11/2022

2/17/2021

9/3/2019

10/31/2018

6/28/2018

Exit

Acquired

Reverse Merger

Acquired

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

9

10

10

10

10

California Institute of Regenerative Medicine Partners & Customers

6 Partners and customers

California Institute of Regenerative Medicine has 6 strategic partners and customers. California Institute of Regenerative Medicine recently partnered with Vector BioMed on August 8, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

8/2/2023

Vendor

United States

Vector BioMed, CIRM Partner on Lentiviral Vector Manufacture

`` The acceleration of CAR-T cell therapy in cancer and hematopoietic stem cells for genetic diseases has created significant demand for custom lentiviral vectors at CIRM and among our IAP partners , '' said Shyam Patel , director of business Development at CIRM .

1

6/13/2023

Vendor

United States

Subscribe to see more

Subscribe to see more

10

11/1/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

8/23/2022

Licensor

United States

Subscribe to see more

Subscribe to see more

10

6/15/2016

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

8/2/2023

6/13/2023

11/1/2022

8/23/2022

6/15/2016

Type

Vendor

Vendor

Partner

Licensor

Partner

Business Partner

Country

United States

United States

United States

United States

United States

News Snippet

Vector BioMed, CIRM Partner on Lentiviral Vector Manufacture

`` The acceleration of CAR-T cell therapy in cancer and hematopoietic stem cells for genetic diseases has created significant demand for custom lentiviral vectors at CIRM and among our IAP partners , '' said Shyam Patel , director of business Development at CIRM .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.